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Abstract
Background: Evidence for protection of preterm born infants from invasive pneumococcal disease (IPD) by 7-
valent pneumococcal conjugate vaccination (PCV7) is relatively sparse. Data from randomized trials is based on
relatively small numbers of preterm born children.
Methods: We report data from active prospective surveillance of IPD in children in Germany. The cohorts of
preterm born children in 2000 and 2007 and the respective whole birth cohorts are compared regarding
occurrence of IPD.
Results: After introduction of PCV7 we observed a reduction in the rate of IPD in preterm born infants comparing
the 2000 and 2007 birth cohort. The rate of IPD among the whole birth cohorts was reduced from 15.0 to 8.5
notifications per 100,000 (P < .001). The impact among the preterm birth cohort was comparable: A reduction in
notification rate from 26.1 to 16.7 per 100,000 comparing the 2000 with the 2007 preterm birth cohort (P = .39).
Preterm born infants with IPD were either unvaccinated or vaccinated delayed or incomplete.
Conclusions: This adds to evidence that PCV7 also protects preterm born infants effectively from IPD. Preterm
born infants should receive pneumococcal vaccination according to their chronological age.
Background
Streptococcus pneumoniae is a major source of morbid-
ity and mortality worldwide. It is estimated that S. pneu-
moniae causes around 11% of all deaths in children
aged 1-59 months [1]. Invasive pneumococcal disease
(IPD) in children is associated with considerable case-
fatality rates and rates of sequelae, even in industrialized
countries [2-6]. In February 2000, a 7-valent pneumo-
coccal conjugate vaccine (PCV7) was licensed in the US.
This vaccine offers the possibility for a general vaccina-
tion program in infants and toddlers. Starting from
2001, a strong decrease of IPD incidence in children has
been reported from the US [7-11]. Several European
countries have shown decreases in the incidence of IPD
after introduction of PCV7 [12] including Germany [13].
Preterm born infants are at higher risk for infectious
diseases like invasive pneumococcal disease (IPD), with
the highest risk in early infancy [14]. Vaccination of pre-
term born infants is often performed delayed [15]. Effi-
cacy of heptavalent pneumococcal conjugate vaccination
(PCV7) to protect infants younger than 2 years from
IPD was shown in a randomized controlled trial [16].
Evidence from this trial also suggested a good protection
of preterm born infants [17]. A study on immunogeni-
city of PCV7 from Italy in 46 preterm born infants
showed antibody levels comparable to those in 46 full
term infants [18]. However, another immunogenicity
study from the UK with 68 preterm infants and 69 full
term infants showed lower antibody levels among the
preterm infants [19]. Furthermore, the lack of evidence
of protection by PCV7 of preterm infants born before
32 weeks gestation from IPD has been stressed [20].
General vaccination with PCV7 of all infants was recom-
mended in July 2006 in Germany. In this study we eval-
uate the impact of PCV7 on IPD in preterm born
infants in Germany comparing children born in 2000
with those born in 2007. * Correspondence: simon.rueckinger@med.uni-muenchen.de
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We report data from active prospective surveillance of
IPD in all German pediatric hospitals. Hospitals were
contacted on a monthly basis via postcards to ask if a
case of invasive pneumococcal disease had been
observed the last month. The case definition of IPD was
isolation of Streptococcus pneumoniae from at least one
culture of blood, cerebrospinal fluid, or a sample from
any other normally sterile body site. Cases were
excluded if they did not match the case definition, were
older than 15 years, or double reports. Physicians filled
comprehensive questionnaires on disease manifestation,
outcome, vaccinations, and underlying conditions. There
was a check box specifically asking for preterm birth
and week of gestation of preterm births. Details of the
study have been described elsewhere [13,21,22]. The
study is part of the International Network of Paediatric
Surveillance Units (INoPSU) [23].
Microbiologic laboratories were invited to send pneu-
mococcal strains isolated from a normally sterile body
site to the German National Reference Center for Strep-
tococci, where the species identification was confirmed
and serotyping, using Neufeld’s Quellung method [24],
was performed.
In order to account for a population denominator, the
number of preterm born children (before 37 completed
weeks gestation) was estimated based on the assumption
that about 7% of children in Germany are born preterm.
Based on the hospital surveillance, we compared data
from two preterm birth cohorts: those born in 2000 and
those born in 2007. Infants from both birth cohorts were
under surveillance for at least one and two years at maxi-
mum: 2000-2001 and 2007-2008 respectively. Also based
on the hospital surveillance we compared IPD notifica-
tions for all children (irrespective whether preterm born
or not) for the birth cohorts of the years 2000 and 2007
using the same approach. Numbers on all births in Ger-
many were provided by the Federal Statistical Office Ger-
many. Incidence estimates were calculated based on IPD
notifications from the respective (preterm) birth cohort
reported in the year of birth and the subsequent year.
These total numbers were divided by the respective num-
ber of (preterm) born children. Incidence estimates from
2000-2001 and 2007-2008 were compared using Fisher’s
exact test for difference in proportions.
Because this study is based on retrospective case analy-
sis, without the possibility of identifying individual sub-
jects, only data protection issues are of concern. Consent
of the Bavarian data protection office was given.
Results
Between January 2007 and December 2008, 58 cases of
I P Di nc h i l d r e nb o r ni n2 0 0 7w e r er e p o r t e df r o m
Germany pediatric hospitals compared to 115 cases in
children born in 2000 reported between 2000 and 2001
(Table 1). This corresponds to a reduction in notifica-
tions per 100,000 from 15.0 to 8.5 (P < .001). The
reported number of preterm born children with IPD
was 14 in 2000-2001 and 8 in 2007-2008. This corre-
sponds to a reduction in notification rate from 26.1 to
16.7 per 100,000 comparing the 2000 with the 2007 pre-
term birth cohort (P = .39). Among the 14 cases of IPD
among preterm born children, 9 had information on
serotype and for 7 of these the serotype was included in
PCV7 (14 (3 cases), 18C (2 cases), 19A, 23F, 3, 9V).
Among the preterm born children born in 2000, 6 out
of 14 had a gestational age of less than 32 weeks and
one child had bronchopulmonary dysplasia. Among the
preterm born children born in 2007, 3 out of 8 had a
gestational age of less than 32 weeks and one child had
partial trisomy 15.
Characteristics of the eight IPD cases in children born
preterm in 2007 reported between 2007 and 2008 are
shown in Table 2. Five out of eight cases were born
after the 32
nd week gestation. Four cases were vacci-
nated with PCV7 prior to disease onset. However no
infant had received full vaccination with booster dose
according to the recommended scheme. In two cases a
serotype included in PCV7 was found. These two cases
had not received pneumococcal vaccination prior to dis-
ease onset, although they were at an appropriate age. In
two cases a neurological deficit was reported as outcome
and in one case a cerebral parenchymal damage.
Discussion
Comparing the 2000 and 2007 birth cohorts we have
observed a similar reduction in IPD notifications in pre-
term born children compared to children born at term
after introduction of the general pneumoccal vaccination
programme in Germany. These data suggest that PCV7
vaccination is similarly effective in protecting preterm
born infants from IPD compared to full term children.
Our results add to previous evidence of protection of
preterm born infants from IPD from a randomized con-
trolled trial [17], and studies on immunogenicity of
PCV7 in preterm infants [18,19]. In the randomized
controlled trial 4,340 preterm born children were
enrolled and none of these had IPD in the intervention
group compared to 9 IPD cases in the control group.
The about 2-fold higher IPD rates among preterm born
children we observed are in line with the finding of a
1.6-fold increased risk of IPD in preterm born children
from this clinical trial [17].
It is relatively unlikely that the reduction of IPD inci-
dence among preterm born children was influenced by
herd immunity. The vaccination program was not fully
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that less than 80% of all children born in 2007 were
fully vaccinated [13]. Therefore, it is most likely that
these results rather reflect direct protection of the
vaccine.
The distribution of gestational age among preterm
born children with IPD from the 2007 preterm birth
cohort does not suggest that infants born before 32
weeks gestation are protected considerably less than
infants born after 32 weeks gestation. However, case
numbers and therefore statistical power may be too
small for a conclusive answer and future studies on the
effectiveness of PCV7 in very preterm born infants are
needed.
Timing of vaccination in preterm infants born in
2007 was not in accordance with the German guide-
lines that advocate vaccination at 2, 3, 4, and 11-14
months. Four cases had received no vaccination
although they were at an appropriate age before dis-
ease onset. This confirms concerns about the tendency
towards delayed immunization of preterm infants,
exposing them for infection at time points where they
are most vulnerable [15].
This study is somehow limited by the fact that the
exact number of preterm born infants in Germany is
unknown. There are complete surveys on births in some
parts of Germany. Data from these surveys suggest that
the proportion of preterm born infants was stable
regarding the study period (personal communication by
Dr. Lack, Bavarian Quality Assurance Institute for Medi-
cal Care, Munich, Germany). Another limitation is the
lack of trend data, e.g. for the birth cohorts between
2001 and 2006. The hospital surveillance system was
confined to vaccinated cases between 2003 and 2006.
Furthermore, a recommendation to vaccinate preterm
born children with PCV7 was issued in 2001. Therefore
the 2000 birth cohort represents the only birth cohort
for which data on unvaccinated preterm born children
could be analysed.
Conclusions
In summary this study adds to evidence that PCV7 also
protects preterm born infants from IPD and points to
the need for timely vaccination of preterm children
according to their chronological age as recommended e.
g. by the German Standing Vaccination Committee
Table 1 Births and preterm births in 2000 and 2007 in Germany and invasive pneumococcal disease (IPD) cases
reported from these birth cohorts in 2000-2001 and 2007-2008 respectively.
Birth cohort
2000 2007 Percentage decrease P
a
All infants:
Births 766,999 684,862
IPD notifications 115 58
IPD notifications per 100,000 15.0 8.5 43.3 < .001
Preterm born infants:
Births
b 53,690 47,940
IPD notifications 14 8
IPD notifications per 100,000 26.1 16.7 36.0 .39
a P value calculated with Fisher’s exact test.
b Estimated based on a prevalence of preterm birth of 7%.
Table 2 Characteristics of invasive pneumococcal disease (IPD) of preterm births born in 2007 from surveillance 2007-
2008.
ID Sex Gestational week IPD at age (months) PCV7 vaccination Sequelae Serotype
1 M 24 9 8 months Neurological deficit 15B
2 F 30 8 - Cerebral parenchymal damage 23Fa
3 M 31 22 4, 5, and 7 months - Unknown
4 F 35 20 - Unclear 14a
5 F 36 9 3 and 4 months - 10A
6 F 36 3 - - Unknown
7 M 36 6 - - Unknown
8 M 37 5 4 months Neurological deficit 19A
a Serotype included in PCV7.
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mittee on Infectious Diseases [25].
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